drug · small molecule
Opzelura
Marketedupdated 6mo agoby $INCY INCYTE CORP🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 6 investigational indications.
targets
Tyrosine-protein kinase JAK1Tyrosine-protein kinase JAK2
all catalysts(0)
nothing on the calendar yet
Trials studying Opzelura
- phase2A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis
- phase3A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
- phase1A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 24, 2026
4 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (112)
- May 5, 2041method-of-use (U-3550)US 11602536
- Sep 4, 2040method-of-use (U-3505)US 11510923
- Sep 4, 2040method-of-use (U-3505)US 11590137
- Jul 28, 2040method-of-use (U-4151)US 12233067
- Jun 10, 2040method-of-use (U-3551)US 11590138
- Nov 20, 2031patentUS 10758543*PED
- Nov 20, 2031patentUS 10869870*PED
- Nov 20, 2031patentUS 11219624*PED
- May 20, 2031formulationUS 107585434.5y
- May 20, 2031method-of-use (U-3229)US 108698704.5y
- May 20, 2031formulationUS 112196244.5y
- May 20, 2031formulationUS 115714254.5y
- May 20, 2031method-of-use (U-3404)US 115901364.5y
- May 20, 2031formulationUS 122264194.5y
- May 20, 2031formulationUS 125443814.5y
- May 20, 2031formulationUS 125645934.5y
- Dec 12, 2028patentUS 10016429*PED2.1y
- Dec 12, 2028patentUS 10016429*PED2.1y
- Dec 12, 2028patentUS 10016429*PED2.1y
- Dec 12, 2028patentUS 10016429*PED2.1y
- Dec 12, 2028patentUS 10016429*PED2.1y
- Dec 12, 2028patentUS 10610530*PED2.1y
- Dec 12, 2028patentUS 8722693*PED2.1y
- Dec 12, 2028patentUS 8722693*PED2.1y
- Dec 12, 2028patentUS 8722693*PED2.1y
- Dec 12, 2028patentUS 8722693*PED2.1y
- Dec 12, 2028patentUS 8722693*PED2.1y
- Dec 12, 2028patentUS 8722693*PED2.1y
- Dec 12, 2028patentUS 8822481*PED2.1y
- Dec 12, 2028patentUS 8822481*PED2.1y
- Dec 12, 2028patentUS 8822481*PED2.1y
- Dec 12, 2028patentUS 8822481*PED2.1y
- Dec 12, 2028patentUS 8822481*PED2.1y
- Dec 12, 2028patentUS 8822481*PED2.1y
- Dec 12, 2028patentUS 8829013*PED2.1y
- Dec 12, 2028patentUS 8829013*PED2.1y
- Dec 12, 2028patentUS 8829013*PED2.1y
- Dec 12, 2028patentUS 8829013*PED2.1y
- Dec 12, 2028patentUS 8829013*PED2.1y
- Jun 24, 2028patentUS 7598257*PED1.6y
- Jun 24, 2028patentUS 7598257*PED1.6y
- Jun 24, 2028patentUS 7598257*PED1.6y
- Jun 24, 2028patentUS 7598257*PED1.6y
- Jun 24, 2028patentUS 7598257*PED1.6y
- Jun 24, 2028patentUS 7598257*PED1.6y
- Jun 24, 2028patentUS 8415362*PED1.6y
- Jun 24, 2028patentUS 8415362*PED1.6y
- Jun 24, 2028patentUS 8415362*PED1.6y
- Jun 24, 2028patentUS 8415362*PED1.6y
- Jun 24, 2028patentUS 8415362*PED1.6y
- Jun 24, 2028patentUS 8415362*PED1.6y
- Jun 12, 2028method-of-use (U-3230)US 100164291.6y
- Jun 12, 2028method-of-use (U-3230)US 100164291.6y
- Jun 12, 2028method-of-use (U-3230)US 100164291.6y
- Jun 12, 2028method-of-use (U-3230)US 100164291.6y
- Jun 12, 2028method-of-use (U-3230)US 100164291.6y
- Jun 12, 2028method-of-use (U-3229)US 106105301.6y
- Jun 12, 2028compositionUS 87226931.6y
- Jun 12, 2028compositionUS 87226931.6y
- Jun 12, 2028compositionUS 87226931.6y
- Jun 12, 2028compositionUS 87226931.6y
- Jun 12, 2028compositionUS 87226931.6y
- Jun 12, 2028compositionUS 87226931.6y
- Jun 12, 2028method-of-use (U-3229)US 88224811.6y
- Jun 12, 2028method-of-use (U-3230)US 88224811.6y
- Jun 12, 2028method-of-use (U-3230)US 88224811.6y
- Jun 12, 2028method-of-use (U-3230)US 88224811.6y
- Jun 12, 2028method-of-use (U-3230)US 88224811.6y
- Jun 12, 2028method-of-use (U-3230)US 88224811.6y
- Jun 12, 2028method-of-use (U-3228)US 88290131.6y
- Jun 12, 2028method-of-use (U-3227)US 88290131.6y
- Jun 12, 2028method-of-use (U-3227)US 88290131.6y
- Jun 12, 2028method-of-use (U-3227)US 88290131.6y
- Jun 12, 2028method-of-use (U-3228)US 88290131.6y
- Dec 24, 2027compositionUS 75982571.1y
- Dec 24, 2027compositionUS 75982571.1y
- Dec 24, 2027compositionUS 75982571.1y
- Dec 24, 2027compositionUS 75982571.1y
- Dec 24, 2027compositionUS 75982571.1y
- Dec 24, 2027compositionUS 75982571.1y
- Dec 24, 2027compositionUS 84153621.1y
- Dec 24, 2027compositionUS 84153621.1y
- Dec 24, 2027compositionUS 84153621.1y
- Dec 24, 2027compositionUS 84153621.1y
- Dec 24, 2027compositionUS 84153621.1y
- Dec 24, 2027compositionUS 84153621.1y
- Jun 12, 2027patentUS 10639310*PED204d
- Jun 12, 2027patentUS 9079912*PED204d
- Jun 12, 2027patentUS 9079912*PED204d
- Jun 12, 2027patentUS 9079912*PED204d
- Jun 12, 2027patentUS 9079912*PED204d
- Jun 12, 2027patentUS 9079912*PED204d
- Jun 12, 2027patentUS 9079912*PED204d
- Jun 12, 2027patentUS 9814722*PED204d
- Jun 12, 2027patentUS 9814722*PED204d
- Jun 12, 2027patentUS 9814722*PED204d
- Jun 12, 2027patentUS 9814722*PED204d
- Jun 12, 2027patentUS 9814722*PED204d
- Jun 12, 2027patentUS 9974790*PED204d
- Dec 12, 2026method-of-use (U-3229)US 1063931022d
- Dec 12, 2026method-of-use (U-3230)US 907991222d
- Dec 12, 2026method-of-use (U-3230)US 907991222d
- Dec 12, 2026method-of-use (U-3230)US 907991222d
- Dec 12, 2026method-of-use (U-3230)US 907991222d
- Dec 12, 2026method-of-use (U-3230)US 907991222d
- Dec 12, 2026method-of-use (U-3229)US 907991222d
- Dec 12, 2026method-of-use (U-3230)US 981472222d
- Dec 12, 2026method-of-use (U-3230)US 981472222d
- Dec 12, 2026method-of-use (U-3230)US 981472222d
- Dec 12, 2026method-of-use (U-3230)US 981472222d
- Dec 12, 2026method-of-use (U-3230)US 981472222d
- Dec 12, 2026method-of-use (U-3229)US 997479022d
FDA exclusivities (33)
- Mar 22, 2029PEDPediatric (6mo bonus)2.3y
- Mar 22, 2029PEDPediatric (6mo bonus)2.3y
- Mar 22, 2029PEDPediatric (6mo bonus)2.3y
- Mar 22, 2029PEDPediatric (6mo bonus)2.3y
- Mar 22, 2029PEDPediatric (6mo bonus)2.3y
- Sep 22, 2028ODE-373Orphan Drug (7y)1.8y
- Sep 22, 2028ODE-373Orphan Drug (7y)1.8y
- Sep 22, 2028ODE-373Orphan Drug (7y)1.8y
- Sep 22, 2028ODE-373Orphan Drug (7y)1.8y
- Sep 22, 2028ODE-373Orphan Drug (7y)1.8y
- Sep 18, 2028NPPNew Product (3y)1.8y
- Nov 24, 2026PEDPediatric (6mo bonus)4d
- Nov 24, 2026PEDPediatric (6mo bonus)4d
- Nov 24, 2026PEDPediatric (6mo bonus)4d
- Nov 24, 2026PEDPediatric (6mo bonus)4d
- Nov 24, 2026PEDPediatric (6mo bonus)4d
- Jun 19, 2026PEDPediatric (6mo bonus)
- Jun 19, 2026PEDPediatric (6mo bonus)
- Jun 19, 2026PEDPediatric (6mo bonus)
- Jun 19, 2026PEDPediatric (6mo bonus)
- Jun 19, 2026PEDPediatric (6mo bonus)
- May 24, 2026ODE-238Orphan Drug (7y)
- May 24, 2026ODE-238Orphan Drug (7y)
- May 24, 2026ODE-238Orphan Drug (7y)
- May 24, 2026ODE-238Orphan Drug (7y)
- May 24, 2026ODE-238Orphan Drug (7y)
- Jan 18, 2026PEDPediatric (6mo bonus)
- Dec 19, 2025M-285Method (3y)
- Dec 19, 2025M-285Method (3y)
- Dec 19, 2025M-285Method (3y)
- Dec 19, 2025M-285Method (3y)
- Dec 19, 2025M-285Method (3y)
- Jul 18, 2025I-896Indication (3y)
News(10)
- Lilly adds to buyout streak with $1.5B purchase of startup CalytrixLilly’s 15th announced acquisition this year — by far the most in the biopharmaceutical sector — centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms.biopharma_dive · 3d ago
- Alethio raises $90M to target rare blood cancersThe startup is working on a medicine one of its investors claimed could have a broader reach than other approved drugs for a group of conditions known as myeloproliferative neoplasms.biopharma_dive · 14d ago
- Karyopharm files for bankruptcy, looks to merger with Ayrmid for life raftDebtor-in-process financing up to $55 million could keep the lights on at Karyopharm Therapeutics for its multiple myeloma and myelofibrosis programs as the biotech waits to see if its union with A…biospace · 16d ago
- Karyopharm files Chapter 11, lines up Ayrmid as lead bidder in planned mergerIn an answer to Karyopharm's cash crisis, Irish biotech Ayrmid has agreed to make the first bid on the struggling biopharma's assets in a court supervised auction, teeing up a potential hematology…fiercebiotech · 17d ago
- Geron’s Rytelo stumbles in phase 3 as Novartis gears up for post-JAK inhibitor blood cancer bidGeron has discontinued a phase 3 trial of its Rytelo in JAK inhibitor-pretreated myelofibrosis after an independent data monitoring committee ruled that the study was unlikely to succeed, just as N…fiercebiotech · 21d ago
- ESMO: Why Incyte sees itself ‘neck and neck’ with RevMed in KRAS G12D pancreatic cancer raceIncyte has pointed to a spread of phase 1 data for its KRAS G12D inhibitor as evidence that the company has a worthy rival to Revolution Medicines in this increasingly competitive cancer space.fiercebiotech · 25d ago
- Merck KGaA bets on RNAi with $1.3B Silence buyoutThe acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.biopharma_dive · 1mo ago
- Mid-cap biotechs join Trump’s latest round of drug pricing dealsFocused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.biopharma_dive · 2mo ago
- 9 midsize drugmakers climb aboard Trump’s MFN trainAstellas Pharma, BridgeBio, BeOne Medicines and six other large biotechs join the 17 Big Pharmas that previously signed on to President Donald Trump’s Most Favored Nation (MFN) drug pricing program…biospace · 2mo ago
- FDA OKs Takeda, Protagonist drug for rare blood cancerThe clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.biopharma_dive · 2mo ago
Data sources
last refreshed 7h ago
Found something off?
comments(0)
5-min edit window · permanent after that